• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Cingulate, Indegene Partner on ADHD Commercialization Candidate


Pending FDA approval, agreement expected to support once-daily stimulant medication.

According to a report by GlobeNewswire, Cingulate Inc., a biopharmaceutical company, and Indegene, a life sciences commercialization organization, are collaborating on the biopharmaceutical’s lead candidate CTx-1301 (dexmethylphenidate), developed as a daily stimulant for attention deficit/hyperactivity disorder (ADHD), upon approval from the FDA.

Reportedly, the agreement covers a majority of the commercialization process, including sales, PRMA (pricing, reimbursement, and market access), medical affairs, medical communications, and marketing and commercial operations support. The deal aims to drive revenue with the goal of ensuring predictable cash flow.

“We believe the ability to deploy Indegene’s range of digital best practices and new communications channels will play a large role in the pre-launch preparation, and enable Cingulate to immediately tap into the proven market access, sales force effectiveness and medical commercialization operations critical to a successful launch,” says Timothy Moore, SVP of emerging biotech at Indegene. “We have worked with 19 of the top 20 global pharmaceutical companies, and this joint commercialization agreement expands Indegene’s services to an emerging growth company, positioning Cingulate for success in the event CTx-1301 is approved by the FDA.”

Reference: Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301, March 13, 2023/GlobeNewswire

Related Videos